Journal

Pharmacology research & perspectives
ISSN: 2052-1707
Titre abrégé: Pharmacol Res Perspect
Pays: United States
ID NLM: 101626369

Informations de publication

Date de publication:
12 2019
Historique:
received: 02 05 2019
revised: 08 08 2019
accepted: 29 08 2019
entrez: 19 10 2019
pubmed: 19 10 2019
medline: 7 7 2020
Statut: epublish

Résumé

Dichloroacetate (DCA) is an investigational drug targeting the glycolytic hallmark of cancer by inhibiting pyruvate dehydrogenase kinases (PDK). It is metabolized by GSTZ1, which has common polymorphisms altering enzyme or promoter activity. GSTZ1 is also irreversibly inactivated by DCA. In the first clinical trial of DCA in a hematological malignancy, DiCAM (DiChloroAcetate in Myeloma), we have examined the relationship between DCA concentrations,

Identifiants

pubmed: 31624634
doi: 10.1002/prp2.526
pii: PRP2526
pmc: PMC6783648
doi:

Substances chimiques

Drugs, Investigational 0
Protein Kinase Inhibitors 0
Pyruvate Dehydrogenase Acetyl-Transferring Kinase 0
Dichloroacetic Acid 9LSH52S3LQ
GSTZ1 protein, human EC 2.5.1.-
Glutathione Transferase EC 2.5.1.18

Types de publication

Clinical Trial, Phase II Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e00526

Commentaires et corrections

Type : CommentIn

Informations de copyright

© 2019 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd, British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.

Références

Exp Hematol Oncol. 2015 Apr 21;4:12
pubmed: 25909034
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Environ Health Perspect. 1998 Aug;106 Suppl 4:989-94
pubmed: 9703483
Methods Enzymol. 2005;401:1-8
pubmed: 16399376
Pharmacogenet Genomics. 2015 May;25(5):239-45
pubmed: 25738370
Science. 2009 May 22;324(5930):1029-33
pubmed: 19460998
PLoS One. 2015 Mar 13;10(3):e0119857
pubmed: 25769101
Invest New Drugs. 2014 Jun;32(3):452-64
pubmed: 24297161
Intern Med J. 2015 Jan;45(1):94-105
pubmed: 25582938
J Clin Pharmacol. 2012 Jun;52(6):837-49
pubmed: 21642471
Mol Cancer. 2011 Nov 18;10:142
pubmed: 22093145
Neurology. 2006 Feb 14;66(3):324-30
pubmed: 16476929
Cancer Cell. 2007 Jan;11(1):37-51
pubmed: 17222789
Pharmacogenet Genomics. 2006 May;16(5):307-13
pubmed: 16609361
Blood. 2002 Mar 15;99(6):2185-91
pubmed: 11877296
Br J Cancer. 2013 Jan 15;108(1):170-8
pubmed: 23321518
Invest New Drugs. 2015 Jun;33(3):603-10
pubmed: 25762000
Breast Cancer Res Treat. 2010 Feb;120(1):253-60
pubmed: 19543830
Biochem J. 1998 Jan 1;329 ( Pt 1):191-6
pubmed: 9405293
Br J Cancer. 2008 Oct 7;99(7):989-94
pubmed: 18766181
J Peripher Nerv Syst. 2006 Jun;11(2):135-41
pubmed: 16787511
Biomed Res Int. 2013;2013:946206
pubmed: 24024216
Pediatrics. 2006 May;117(5):1519-31
pubmed: 16651305
Int J Cancer. 2011 Mar 1;128(5):1001-8
pubmed: 20957634
J Exp Clin Cancer Res. 2015 Feb 05;34:14
pubmed: 25652202
Genet Test Mol Biomarkers. 2018 Apr;22(4):266-269
pubmed: 29641284
Blood. 2003 Jun 1;101(11):4569-75
pubmed: 12576322
Cancer Res. 2015 May 15;75(10):2071-82
pubmed: 25769724
Clin Cancer Res. 2016 Nov 15;22(22):5428-5433
pubmed: 28151710
Pharmacogenetics. 2000 Feb;10(1):49-57
pubmed: 10739172
Br J Cancer. 2013 Apr 30;108(8):1624-33
pubmed: 23531700
Sci Transl Med. 2010 May 12;2(31):31ra34
pubmed: 20463368
J Cancer Res Clin Oncol. 2014 Mar;140(3):443-52
pubmed: 24442098
Chem Res Toxicol. 1999 Dec;12(12):1144-9
pubmed: 10604862
Nat Rev Cancer. 2012 Apr 12;12(5):335-48
pubmed: 22495321
Pharmacogenetics. 2001 Nov;11(8):671-8
pubmed: 11692075
Pharmacol Res Perspect. 2019 Oct 08;7(6):e00526
pubmed: 31624634
Biochim Biophys Acta. 2014 Dec;1846(2):617-29
pubmed: 25157892
Oncotarget. 2015 Oct 20;6(32):33568-86
pubmed: 26384349
Cancer Biol Ther. 2014;15(11):1533-41
pubmed: 25482950
Int J Cancer. 2010 Dec 1;127(11):2510-9
pubmed: 20533281
Chem Res Toxicol. 2000 Apr;13(4):231-6
pubmed: 10775321

Auteurs

Dan Dan Tian (DD)

ACRF Department of Cancer Biology and Therapeutics The John Curtin School of Medical Research The Australian National University Canberra ACT Australia.

Samuel K Bennett (SK)

Department of Haematology The Canberra Hospital Garran ACT Australia.

Lucy A Coupland (LA)

ACRF Department of Cancer Biology and Therapeutics The John Curtin School of Medical Research The Australian National University Canberra ACT Australia.

Kathryn Forwood (K)

Department of Haematology The Canberra Hospital Garran ACT Australia.

Yadanar Lwin (Y)

Department of Haematology The Canberra Hospital Garran ACT Australia.

Niloofar Pooryousef (N)

ACRF Department of Cancer Biology and Therapeutics The John Curtin School of Medical Research The Australian National University Canberra ACT Australia.

Illa Tea (I)

ACRF Department of Cancer Biology and Therapeutics The John Curtin School of Medical Research The Australian National University Canberra ACT Australia.

Thy T Truong (TT)

Joint Mass Spectrometry Facility The Australian National University Acton ACT Australia.

Teresa Neeman (T)

Statistical Consulting Unit The Australian National University Acton ACT Australia.

Philip Crispin (P)

Department of Haematology The Canberra Hospital Garran ACT Australia.

James D'Rozario (J)

Department of Haematology The Canberra Hospital Garran ACT Australia.

Anneke C Blackburn (AC)

ACRF Department of Cancer Biology and Therapeutics The John Curtin School of Medical Research The Australian National University Canberra ACT Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH